Elsie Biotechnologies, Inc., a biopharmaceutical company unlocking the full potential of oligonucleotide therapeutics, announced today a research collaboration agreement with GSK plc (NYSE:GSK) to advance the discovery and development of Elsie’s innovative oligonucleotide discovery platform with the aim of finding novel oligonucleotides optimized for safety, efficacy, and delivery. The collaboration combines GSK’s extensive expertise in DNA encoded library technologies with Elsie’s drug discovery platform. The companies will begin an initial research period where GSK and Elsie will explore the platform capabilities. Throughout the research term, GSK may exercise an option to a non-exclusive license from Elsie for the discovery platform and P(V) chemistry technologies to employ in GSK’s own oligonucleotide drug discovery research.
‘Teladoc Will Become A Premier Enterprise Partner’: Why Cathie Wood Is Buying The Dip And Remains Bullish On Teladoc
Virtual healthcare provider Teladoc Health (NYSE: TDOC) has been a favorite stock pick of Cathie Wood, CEO of Ark Invest. After shares dropped 18% on Thursday from second quarter financial results, Wood defended the pick and bought the dip.
